Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms (Q85942967)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045501%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045501%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045501%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Jaroslaw P. Maciejewski

17

object named as

J P Maciejewski

0 references

author name string

V Visconte

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045501%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

P Elson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045501%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

A Tabarroki

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045501%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

A M Jankowska

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045501%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

E Hasrouni

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045501%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Y Sugimoto

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045501%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

H Szpurka

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045501%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

H Makishima

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045501%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

C L O'Keefe

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045501%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

M A Sekeres

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045501%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

A S Advani

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045501%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

M Kalaycio

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045501%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

E A Copelan

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045501%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Y Saunthararajah

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045501%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

S T Olalla Saad

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045501%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

J P Maciejewski

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045501%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

R V Tiu

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045501%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

18 September 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045501%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045501%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045501%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045501%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

78-87

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045501%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2013.269

22 February 2020

exact match

0 references

cites work

DNMT3A Mutations in Acute Myeloid Leukemia

1 reference

12 December 2020

Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

1 reference

12 December 2020

SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes

1 reference

12 December 2020

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

12 December 2020

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

12 December 2020

Clinical effect of point mutations in myelodysplastic syndromes

1 reference

12 December 2020

Acquired mutations in TET2 are common in myelodysplastic syndromes

1 reference

12 December 2020

Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms

1 reference

12 December 2020

RNA modulation of the human DNA methyltransferase 3A.

1 reference

12 December 2020

Mutation in TET2 in myeloid cancers

1 reference

12 December 2020

Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.

1 reference

12 December 2020

Frequent pathway mutations of splicing machinery in myelodysplasia

1 reference

12 December 2020

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

12 December 2020

Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes

1 reference

12 December 2020

MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation

1 reference

12 December 2020

Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms

1 reference

12 December 2020

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

1 reference

12 December 2020

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

1 reference

12 December 2020

Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia

1 reference

12 December 2020

Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes

1 reference

12 December 2020

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

1 reference

12 December 2020

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

1 reference

12 December 2020

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.

1 reference

12 December 2020

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

1 reference

12 December 2020

Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010

1 reference

12 December 2020

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

1 reference

12 December 2020

International scoring system for evaluating prognosis in myelodysplastic syndromes

1 reference

12 December 2020

Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia

1 reference

12 December 2020

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts

1 reference

12 December 2020

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

12 December 2020

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

1 reference

12 December 2020

Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis

1 reference

12 December 2020

Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms

1 reference

12 December 2020

SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts

1 reference

12 December 2020

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

1 reference

12 December 2020

N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2013.269

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24045501%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

22 February 2020

0 references

1 reference